Opko Health (OPK) Has Right Formula for Strong Investor Returns - Cramer - InvestingChannel

Opko Health (OPK) Has Right Formula for Strong Investor Returns – Cramer

ArticleStock Quotes (1) Comments (0)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top NewsMost Read Highlighted

Get AlertsOPK Hot Sheet

BUY ( Up)

Opko Health (NYSE: OPK) shares are higher on the session amid positive comments from its CEO Dr. Phillip Frost with Jim Cramer on Monday night.

Frost noted that Opko’s new vitamin D formulation for the treatment of renal disease will address a U.S. market of about four million patients. Total market opportunity is about $12 billion given there are no current adequate treatments for the disease, Front explained. Japan has a similarly-sized market.

The formulation was the result of a successful acquisition, Frost stated. Another lucrative deal was the October 2011 purchase of Claros.

In addition to purchases, Opko is in several partnerships with larger drug makers and will collect a share of revenue on drugs developer through the collaboration.

Frost pointed to Opko nearly completing a 4K test for prostate health and more information should be available in the “near future.”

Following the discussion, Cramer reiterated his support for Opko. The company has a proven track record and “uncanny” ability to acquire companies with breakthrough performances.

Shares are up 6.5 percent Tuesday.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW